Ojjaara-Momelotinib
Ojjaara is an oral medication for adults with intermediate or high-risk myelofibrosis and anemia. It targets JAK1, JAK2, and ACVR1 to reduce spleen size, relieve symptoms, and improve anemia.
Exxua-Gepirone
Exxua is an extended-release oral antidepressant for adults with major depressive disorder. It selectively activates serotonin 5‑HT1A receptors, offering symptom relief with low risk of sexual side effects.
Velsipity-Etrasimod
Velsipity is a once-daily pill for adults with moderately to severely active ulcerative colitis. It modulates S1P receptors to reduce inflammation and maintain remission.
Pombiliti-Cipaglucosidase Alfa-Atga
Pombiliti, used with Opfolda (miglustat), treats adults with late-onset Pompe disease who aren’t responding to enzyme replacement therapy. It delivers an enzyme to break down muscle-accumulated glycogen, improving muscle strength and lung function.
Rivfloza-Nedosiran
Rivfloza is a once-monthly injection for children more than 2 years old and adults with primary hyperoxaluria type 1. It lowers urine oxalate levels by silencing a liver enzyme, helping protect kidney function.
Rystiggo-Rozanolixizumab-Noli
Rystiggo is a weekly subcutaneous infusion for adults with generalized myasthenia gravis. It lowers harmful antibodies that disrupt communication between nerves and muscles.
Talvey-Talquetamab-Tgvs
Talvey is a bispecific antibody injection for adults with multiple myeloma who have already tried at least four other treatments. It helps the immune system target and kill myeloma cells.
Izervay-Avacincaptad Pegol
Izervay is a monthly injection into the eye to treat geographic atrophy caused by age-related macular degeneration. It slows vision loss by targeting a key protein involved in retinal cell death.
Columvi-Glofitamab-Gxbm
Columvi is an antibody-based therapy for adults with relapsed or refractory diffuse large B-cell lymphoma. It activates the immune system to target and destroy cancer cells when other treatments have failed.
Elrexfio-Elranatamab-Bcmm
Elrexfio is a weekly subcutaneous injection for adults with relapsed or refractory multiple myeloma who have tried at least four prior treatments. It’s a bispecific antibody that directs T cells to attack myeloma cells by targeting BCMA and CD3.
